Business Context and Reporting Period
This Form 8-K was filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on June 16, 2021. The report details the entry into a Material Definitive Agreement with Processa Pharmaceuticals, Inc. regarding the global licensing of the drug candidate RX-3117, excluding China.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt) as it is a current report on a specific event. However, the transaction includes the following financial terms:
- Upfront Consideration: $200,000 cash payment and 44,689 shares of Processa common stock.
- Milestone Payments: Future payments contingent on development/regulatory milestones (e.g., pivotal trial dosing, regulatory approval) and annual sales thresholds.
- Royalties: Ongoing royalties based on annual licensing sales.
- Sub-licensing: Ocuphire is entitled to 32% of any milestone payments Processa receives from sub-license agreements.
Material Changes and Operational Obligations
The primary material change is the transfer of exclusive development, manufacturing, and commercialization rights for RX-3117 to Processa. Processa assumes the cost and expense of these efforts and must meet specific diligence milestones:
- First patient dosed in a clinical trial within 3 years of the effective date.
- First patient dosed in a pivotal trial or a second indication trial within 5 years of the effective date.
Outlook, Risks, and Termination Provisions
The agreement includes termination rights for both parties. Either party may terminate for a material breach if not cured within 120 days of written notice. Processa retains the right to terminate the agreement for any reason upon providing 120 days' prior written notice. The filing notes that the summary is not complete and refers to the full agreement attached as Exhibit 10.1.
Investor Verification Checklist
- Verify the current market value of the 44,689 Processa common shares received as consideration.
- Review the specific definitions of "pivotal trials" and "regulatory approval" in the full License Agreement (Exhibit 10.1) to assess the likelihood of milestone payments.
- Confirm the status of RX-3117 development prior to this transfer to understand the risk profile of the diligence milestones.
- Monitor Processa's financial health to ensure they can meet the diligence milestones and fund the commercialization efforts.